Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 46-13 LORELEI 

A phase II randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole Plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer.

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Marco Colleoni, EIO, Milano, Italy

Statistician
Christian Fesi, ABCSG, Vienna, Austria
Ray Lin, Genentech, South San Francisco, CA, USA

Study Manager
Christiaan McEwen, Sarah Brothers

Lead Trial Coordinator
Holly Shaw

Trial Coordinator

Poonam Jani

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg46_LORELEI@fstrf.org

Date of Activation
August 5, 2014

Targeted Accrual
330


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print